Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.55
NAS:AMAG's Cash to Debt is ranked lower than
86% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:AMAG: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
NAS:AMAG' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.55
Equity to Asset 0.37
NAS:AMAG's Equity to Asset is ranked lower than
80% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AMAG: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
NAS:AMAG' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.73 Max: 0.98
Current: 0.37
0.33
0.98
Interest Coverage 0.67
NAS:AMAG's Interest Coverage is ranked lower than
99% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AMAG: 0.67 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 0.67  Med: No Debt Max: No Debt
Current: 0.67
F-Score: 4
Z-Score: 0.54
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.60
NAS:AMAG's Operating margin (%) is ranked higher than
81% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:AMAG: 10.60 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:AMAG' s Operating margin (%) Range Over the Past 10 Years
Min: -4107.64  Med: -127.78 Max: 26.59
Current: 10.6
-4107.64
26.59
Net-margin (%) -4.87
NAS:AMAG's Net-margin (%) is ranked higher than
69% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:AMAG: -4.87 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:AMAG' s Net-margin (%) Range Over the Past 10 Years
Min: -3696.96  Med: -124.17 Max: 109.19
Current: -4.87
-3696.96
109.19
ROE (%) -2.44
NAS:AMAG's ROE (%) is ranked higher than
74% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:AMAG: -2.44 )
Ranked among companies with meaningful ROE (%) only.
NAS:AMAG' s ROE (%) Range Over the Past 10 Years
Min: -86.79  Med: -24.88 Max: 42.96
Current: -2.44
-86.79
42.96
ROA (%) -0.92
NAS:AMAG's ROA (%) is ranked higher than
76% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:AMAG: -0.92 )
Ranked among companies with meaningful ROA (%) only.
NAS:AMAG' s ROA (%) Range Over the Past 10 Years
Min: -67.05  Med: -22.68 Max: 16.42
Current: -0.92
-67.05
16.42
ROC (Joel Greenblatt) (%) 84.39
NAS:AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:AMAG: 84.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:AMAG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1009.91  Med: -621.53 Max: 615.63
Current: 84.39
-1009.91
615.63
Revenue Growth (3Y)(%) 43.70
NAS:AMAG's Revenue Growth (3Y)(%) is ranked higher than
87% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:AMAG: 43.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:AMAG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31  Med: 19.5 Max: 278.5
Current: 43.7
-31
278.5
» NAS:AMAG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AMAG Guru Trades in Q3 2015

Chuck Royce 19,900 sh (New)
David Dreman 280 sh (New)
Jim Simons 17,660 sh (New)
Scott Black 131,240 sh (New)
Joel Greenblatt 996,545 sh (+95.17%)
Ken Heebner 472,000 sh (-9.58%)
Paul Tudor Jones 15,800 sh (-88.64%)
» More
Q4 2015

AMAG Guru Trades in Q4 2015

Jim Simons 160,260 sh (+807.47%)
David Dreman Sold Out
Ken Heebner Sold Out
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
Joel Greenblatt 216,456 sh (-78.28%)
Scott Black 10,859 sh (-91.73%)
» More
Q1 2016

AMAG Guru Trades in Q1 2016

Paul Tudor Jones 286,200 sh (New)
Jim Simons Sold Out
Scott Black Sold Out
Joel Greenblatt 204,184 sh (-5.67%)
» More
Q2 2016

AMAG Guru Trades in Q2 2016

Steven Cohen 446,300 sh (New)
Joel Greenblatt 411,912 sh (+101.74%)
Paul Tudor Jones 375,500 sh (+31.20%)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PACB, NAS:GBT, NAS:WVE, OTCPK:BPMUF, NAS:BPMC, NAS:MACK, NAS:ANIP, NAS:RPTP, OTCPK:GNFTF, NAS:ZIOP, NAS:CLLS, NAS:INSY, NAS:INSM, NAS:TBRA, NAS:VNDA, NAS:CORT, OTCPK:PHMMF, NAS:ADRO, NAS:FWP, NAS:AVXS » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous ("IV") use; and MuGard, Mucoadhesive Oral Wound Rinse.

AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sells Feraheme to healthcare providers who administer Feraheme within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsources a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.

Ratios

vs
industry
vs
history
Forward P/E 4.34
AMAG's Forward P/E is ranked higher than
92% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. AMAG: 4.34 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 11.84
AMAG's Price/Owner Earnings (ttm) is ranked higher than
82% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. AMAG: 11.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AMAG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.58  Med: 12.17 Max: 23.22
Current: 11.84
4.58
23.22
P/B 0.95
AMAG's P/B is ranked higher than
94% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AMAG: 0.95 )
Ranked among companies with meaningful P/B only.
AMAG' s P/B Range Over the Past 10 Years
Min: 0.68  Med: 2.6 Max: 18.97
Current: 0.95
0.68
18.97
P/S 1.91
AMAG's P/S is ranked higher than
89% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. AMAG: 1.91 )
Ranked among companies with meaningful P/S only.
AMAG' s P/S Range Over the Past 10 Years
Min: 1.52  Med: 8.07 Max: 505.93
Current: 1.91
1.52
505.93
PFCF 6.48
AMAG's PFCF is ranked higher than
93% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. AMAG: 6.48 )
Ranked among companies with meaningful PFCF only.
AMAG' s PFCF Range Over the Past 10 Years
Min: 5.55  Med: 17.25 Max: 127.54
Current: 6.48
5.55
127.54
POCF 6.33
AMAG's POCF is ranked higher than
92% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. AMAG: 6.33 )
Ranked among companies with meaningful POCF only.
AMAG' s POCF Range Over the Past 10 Years
Min: 5.42  Med: 27.63 Max: 1268.5
Current: 6.33
5.42
1268.5
EV-to-EBIT 42.85
AMAG's EV-to-EBIT is ranked lower than
69% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. AMAG: 42.85 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -602.3  Med: -6 Max: 87.5
Current: 42.85
-602.3
87.5
EV-to-EBITDA 12.12
AMAG's EV-to-EBITDA is ranked higher than
68% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMAG: 12.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.9 Max: 367.1
Current: 12.12
-148.3
367.1
Current Ratio 2.24
AMAG's Current Ratio is ranked lower than
73% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. AMAG: 2.24 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 7.92 Max: 54.4
Current: 2.24
1.65
54.4
Quick Ratio 2.11
AMAG's Quick Ratio is ranked lower than
70% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. AMAG: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 7.46 Max: 54.33
Current: 2.11
1.4
54.33
Days Inventory 143.25
AMAG's Days Inventory is ranked lower than
53% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. AMAG: 143.25 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 143.25  Med: 473.03 Max: 1713.48
Current: 143.25
143.25
1713.48
Days Sales Outstanding 54.62
AMAG's Days Sales Outstanding is ranked higher than
56% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. AMAG: 54.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.61  Med: 33.62 Max: 581.14
Current: 54.62
11.61
581.14
Days Payable 31.98
AMAG's Days Payable is ranked lower than
67% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. AMAG: 31.98 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 20.23  Med: 174.87 Max: 6362.77
Current: 31.98
20.23
6362.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. AMAG: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -7.4 Max: 0.7
Current: -17.3
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.87
AMAG's Price/Projected FCF is ranked higher than
92% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. AMAG: 0.87 )
Ranked among companies with meaningful Price/Projected FCF only.
AMAG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.84  Med: 8.58 Max: 96.83
Current: 0.87
0.84
96.83
Price/Median PS Value 0.24
AMAG's Price/Median PS Value is ranked higher than
93% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. AMAG: 0.24 )
Ranked among companies with meaningful Price/Median PS Value only.
AMAG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.44 Max: 138.58
Current: 0.24
0.23
138.58
Earnings Yield (Greenblatt) (%) 2.37
AMAG's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. AMAG: 2.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMAG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 3 Max: 7.2
Current: 2.37
1.1
7.2

More Statistics

Revenue (TTM) (Mil) $441.6
EPS (TTM) $ -0.66
Beta0.91
Short Percentage of Float30.24%
52-Week Range $17.92 - 44.48
Shares Outstanding (Mil)34.15

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 534 622 575 598
EPS ($) 4.61 5.67 3.84 4.11
EPS w/o NRI ($) 4.61 5.67 3.84 4.11
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:AMAG

Headlines

Articles On GuruFocus.com
Steven Cohen Buys AMAG Pharmaceuticals Jul 29 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales... Sep 07 2016
AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales... Sep 07 2016
ETF’s with exposure to AMAG Pharmaceuticals, Inc. : September 6, 2016 Sep 06 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conference Sep 01 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conference Sep 01 2016
Why Do Hedge Funds Like AMAG Pharmaceuticals? Aug 30 2016
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : August... Aug 25 2016
ETF’s with exposure to AMAG Pharmaceuticals, Inc. : August 24, 2016 Aug 24 2016
AMAG PHARMACEUTICALS INC. Financials Aug 18 2016
ETF’s with exposure to AMAG Pharmaceuticals, Inc. : August 12, 2016 Aug 12 2016
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
AMAG Pharmaceuticals, Inc. (AMAG) Is An Attractive Contrarian Entry Aug 11 2016
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : August... Aug 11 2016
Edited Transcript of AMAG earnings conference call or presentation 9-Aug-16 12:00pm GMT Aug 09 2016
AMAG Pharma Posts Big Q2 Beat On The Bottom Line Aug 09 2016
AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 09 2016
AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Aug 09 2016
AMAG Pharmaceuticals reports 2Q loss Aug 09 2016
AMAG Pharmaceuticals reports 2Q loss Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)